Olanzapine Versus Placebo for Moderately Emetogenic Chemotherapy

A Prospective Randomized, Double-blind Controlled Trial of Olanzapine Versus Placebo in Addition to Ondansetron Plus Dexamethasone As Antiemetic Prophylaxis in Patients Receiving Moderately Emetogenic Chemotherapy

A study comparing efficacy of olanzapine versus placebo to prevent nausea and vomiting from moderate emetic risk chemotherapy

A randomized study comparing olanzapine versus placebo in addition to standard antiemetic regimen for preventing nausea and vomiting from moderately emetogenic chemotherapy

Inclusion Criteria:

• histologically confirmed cancer patients who will be started on first dose of oxaliplatin, irinotecan or carboplatin
• age of >18 years old

Exclusion Criteria:

• pregnancy or breast feeding
• has emetic episode within 24 hours
• gut obstruction
• uncontrolled brain metastasis
• allergy to or current use of olanzapine
• concomittant moderate or high emetogenic chemotherapy on day 2-5
• Total bilirubin > 2 mg/dl or creatinine clearance < 30 ml/min
• unable to swallow drug